France Seeks Answers on Lancet’s Hydroxychloroquine Study
(Bloomberg) --
The French government wrote to the Lancet to request a review of the raw data used in a now controversial study into the effects of an old malaria drug called hydroxychloroquine to treat Covid-19.
Health minister Olivier Veran wrote to the scientific journal with questions about the underlying data after it was criticized for the data used in the study, French government spokeswoman Sibeth Ndiaye said after a cabinet meeting Wednesday.
The use of hydroxychloroquine has become politicized after U.S. President Donald Trump's repeated endorsements of the treatment. France ruled against using the medicine for Covid-19 last week after the research published in The Lancet, which pointed to a higher risk of death from taking the medicine.
The French suspension was based on more studies than just the Lancet's, according to Ndiaye.
One of the drug's foremost champions is a French doctor from Marseilles, Didier Raoult. The Lancet and another prestigious medical journal said late Tuesday they have significant concerns about a database that was used to look at how older drugs, including hydroxychloroquine, may work for the new coronavirus.
©2020 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
